ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.442,52
0,11%
S&P 500
6.118,71
0,53%
Dow Jones
44.565,07
0,00%
Euro vs US Dollar
1,04726
0,55%
Bitcoin
105.181,93
1,17%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Prothena Corporation PLC (PRTA)

  7. Prothena Corporation PLC (PRTA) News

PRTA

Prothena (PRTA)

Prothena Corporation PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PRTA
DatumZeitQuelleÜberschriftSymbolFirma
04/01/202501h45Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:PRTAProthena Corporation PLC
30/12/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
30/12/202422h05Business WireProthena Announces Board of Directors UpdateNASDAQ:PRTAProthena Corporation PLC
19/12/202407h05Business WireRoche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s DiseaseNASDAQ:PRTAProthena Corporation PLC
13/11/202413h00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PRTAProthena Corporation PLC
12/11/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
12/11/202422h05Business WireProthena Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
05/11/202422h05Business WireProthena to Report Third Quarter 2024 Financial Results on November 12NASDAQ:PRTAProthena Corporation PLC
04/10/202400h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
04/10/202400h57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
27/09/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
27/09/202422h05Business WireProthena Announces Leadership Team UpdatesNASDAQ:PRTAProthena Corporation PLC
29/08/202422h05Business WireProthena to Participate in Upcoming Healthcare ConferencesNASDAQ:PRTAProthena Corporation PLC
08/08/202423h13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRTAProthena Corporation PLC
08/08/202422h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRTAProthena Corporation PLC
08/08/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
08/08/202422h05Business WireProthena Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/08/202422h05Business WireProthena to Report Second Quarter 2024 Financial Results on August 8NASDAQ:PRTAProthena Corporation PLC
28/05/202422h05Business WireProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development CollaborationNASDAQ:PRTAProthena Corporation PLC
17/05/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
17/05/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
17/05/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
17/05/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
08/05/202422h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRTAProthena Corporation PLC
08/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
08/05/202422h05Business WireProthena Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/05/202422h05Business WireProthena to Report First Quarter 2024 Financial Results on May 8NASDAQ:PRTAProthena Corporation PLC
15/04/202422h05Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaNASDAQ:PRTAProthena Corporation PLC
06/03/202403h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
06/03/202403h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
 Showing the most relevant articles for your search:NASDAQ:PRTA

Kürzlich von Ihnen besucht

TG
E0P
Enphase Energy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten